Clinical Protocols

Oncology Division

Oncology Clinical Trials

 

 

Hematology Division

Click on the title of a protocol to view its description in ClinicalTrials.gov.
 

Disease Protocol (Sponsor) Status PI/Contact Comments
Iron overload/MDS Myelodysplastic Syndromes (MDS) Event Free Survival With Iron Chelation Therapy Study (TELESTO) (Novartis) Open to enrollment PI: Morey Blinder
Contact: Morey Blinder
mblinder@dom.wustl.edu
Low/Int-1 MDS Transfusion Dependent
Iron deficiency Distribution of Iron Isotopes 56Fe and 54Fe in the Serum of Iron Deficiency Anemia and Anemia of Chronic Disease Patients (Internal) Open PI: Mitch Scott
Contact: Morey Blinder
mblinder@dom.wustl.edu
Suspected iron deficiency of ACD in pre-menopausal women
Thrombosis ATTRACT (NIH) Ongoing; closed to enrollment PI: Suresh Vedantham
Contact: Morey Blinder
mblinder@dom.wustl.edu
New DVT
Atypical HUS Atypcial Hemolytic-Uremic Syndrome (aHUS) Registry (Alexion) Open to enrollment PI: Elaine Majerus
Contact: Lisa Garrett
lgarrett@dom.wustl.edu
Atypical HUS
Banking Laboratory Studies Blood Acquistion for Investigation of Thrombotic Disorders (NIH) Open PI: Elaine Majerus
Contact: Lisa Garrett
lgarrett@dom.wustl.edu
Thrombosis Banking
PNH Paroxysmal Nocturnal Hemoglobinuria (PNH) Registry (Alexion) Open to enrollment PI: Elaine Majerus
Contact: Lisa Garrett
lgarrett@dom.wustl.edu
PNH Registry
Hemophilia/Bleeding American Thrombosis and Hemostasis Network Data Collection Open PI: Elaine Majerus
Contact: Bill Berger
bberger@wustl.edu
Sickle Cell Disease Safety, Pharmacokinetic, and Pharmacodynamic Study of NKTT120 in Adult Patients With Stable Sickle Cell Disease (SCD) (NKT Therapeutics) Ongoing; closed to enrollment PI: Elaine Majerus
Contact: Lisa Garrett
lgarrett@dom.wustl.edu
Hb SS and S Beta Null
Sickle Cell Disease A Phase II Trial of Regadenoson in Sickle Cell Anemia (Dana-Farber Cancer Institute) Open to enrollment PI: Elaine Majerus
Contact: Lisa Garrett
lgarrett@dom.wustl.edu
HbSS and S Beta Null
Chuvash polycythemia Ruxolitinib for Chuvash Polycythemia (WU/Incyte) Open PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Compassionate-use study with ruxolitinib for Chuvash polycythemia
Myelofibrosis Momelotinib Versus Ruxolitinib in Subjects With Myelofibrosis (Gilead) Ongoing; closed to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
No prior JAKi therapy
Polycythemia Vera or Essential Thrombocythemia Safety and Efficacy of Momelotinib in Subjects With Polycythemia Vera or Essential Thrombocythemia (Gilead) Ongoing; closed to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
No prior JAKi therapy
Myelofibrosis Oral Pacritinib Versus Best Available Therapy to Treat Myelofibrosis With Thrombocytopenia (PAC326)) (CTI) Open to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Prior JAKi therapy allowed
Myelofibrosis Efficacy of Momelotinib Versus Best Available Therapy in Anemic or Thrombocytopenic Subjects With Primary Myelofibrosis (MF), Post-polycythemia Vera MF, or Post-essential Thrombocythemia MF (Gilead) Open to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
Prior JAKi therapy allowed
Polycythemia Vera Prospective Observational Study Of Patients With Polycythemia Vera In US Clinical Practices (REVEAL) (Incyte) Open to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
CNL/aCML Ruxolitinib Phosphate in Treating Patients With Chronic Neutrophilic Leukemia or Atypical Chronic Myeloid Leukemia (Incyte/OHSU) Open to enrollment PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
Polycythemia Vera or Essential Thrombocythemia Long-term Safety and Efficacy of Momelotinib in Subjects With Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, Polycythemia Vera or Essential Thrombocythemia (Gilead) Enrolling by invitation only PI: Stephen Oh
Contact: Karyn Gordon
kgordon@dom.wustl.edu
314-362-0156
 
TTP/microangiopathy Low Dose Rituximab in Thrombotic Thrombocytopenic Purpura Open to enrollment PI: Evan Sadler
Contact: Leili Dolatshahi
dolatshahi_l@wustl.edu
Low dose Rituximab for TTP